Member Info for Moorscloud

Like your early morning thoughts on Vlad's silence Chris0 and you could well be right. Then again maybe he's just been sitting in a peaceful empty green space drinking in the beauty of the world around him, pondering the enormity of the wonderful life-saving good his discoveries are now on the path to delivering. Deep breaths lth.

Shame you're returned to your old ways HT - was really enjoyed the last few days when you were being the scourge of the trolls not the holders. Also rather assuming that the instant response to Hemo's rns - so like what happened at He1 last week - is well within the comprehension and experience of those who really know how the stock market actually works. And once again the transfer from the impatient to the patient" quotation leaps to mind: many here clearly need to assimilate this.

Not so much a p**s take Trippy as a share take: from the impatient to the patient, as it should be.

Patience pays.

Some with enough "brain" not to be so rude - perhaps you'd like to explain the effect of being sets not MMs to us simpletons please.

Mr India will surely be delighted to be in that header list but otherwise I echo everything you say.

LOL Haddy :))

Spot on Dhub :)

Well we are starting from a base now of almost double of sp before t the holding rns - got to be good.

JHFH / HH / Haywain / Dhub et al where are you? :)

Surely a better breakfast than that for you TillyW and us all :))) Well done Mr Jinx - who could change his name now :)

9 February 2024

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

FDA Consents to Phase I Trials of HEMO-CAR-T

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has been informed by the U.S. Federal Food and Drug Administration ("FDA") that it has lifted the clinical hold on the Investigational New Drug (IND) application for HEMO-CAR-T for the treatment of acute myeloid leukemia ("AML"). The FDA confirmed that the Company had addressed all issues identified in its prior clinical hold letter satisfactorily and consents to the Company proceeding with its Phase I clinical study of HEMO-CAR-T.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are extremely pleased with the FDA's decision to lift the clinical hold. We now look forward to accelerating clinical development of HEMO-CAR-T and to offering patients a potentially life-saving treatment. The removal of the clinical hold was made possible by the hard work and dedication of the entire Hemogenyx Pharmaceuticals team and its Board of Directors and advisors."

Mr Jinx I believe! We are all behind you :)

Following on from PK1/TillyW's point about the value of the increased sp, there is likely to be at least the material benefit from the delay due to the clinical hold in June when the sp was around 2.3. Would make up for some of the challenging wait...

Asleep - idiot or liar. Filtered.

Most likely answer is just that the FDA are rather busy perhaps. Wonder if anyone has an idea how many applications are being processed at the same time.

The lack of scope for leak could mean that there aren't likely to be so many people hoping to dash in at the last second - because that last second could literally be any second! - but are waiting for the rns to commit and therefore could well be buyers who are more interested in Hemo's long term future than simply a quick kill.

Now there's a first ever post on LSE!

Saint68 I think

Heading clearly a typo - should have been "Warped".

Really hope someone here - or the Poly IR Team - has the time and energy to explain to this person quite how wrong they are.